NASDAQ:RANI
Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc.'s revenue grew 58.9% in fiscal 2025 to $1.6M while operating margin rose to −2346.0%. Free cash flow was −$18.8M, −1151.4% of revenue, and the diluted share count rose 132.3%.Summary generated from Rani Therapeutics Holdings, Inc.'s SEC filings. Latest annual report filed Mar 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$1.6M
Revenue growth+58.9%
Revenue, 5-yr CAGR+28.7%
Gross marginn/a
Operating margin−2346.0%
Net margin−1817.1%
ROIC−160.9%
Return on equity−169.6%
Debt / equity0.00
Free cash flow−$18.8M
FCF margin−1151.4%
Share count change+132.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 3 | 0 | 0 | 1 | 2 |
| Operating income | −52 | −63 | −66 | −53 | −38 |
| Net income | −8 | −31 | −34 | −30 | −30 |
| Free cash flow | −33 | −48 | −52 | −36 | −19 |
Recent filings
- 4Insider transaction report
Sep 29, 2026 - 4Insider transaction report
Sep 29, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KResults of operations and financial condition
Aug 13, 2026 - 8-KDirector or officer change
Aug 4, 2026 - 8-KDirector or officer change
Jun 30, 2026 - 8-KResults of a shareholder vote
May 29, 2026 - 8-KOther events
May 27, 2026